Clinical trials: Envafolimab
Efficacy and Safety
Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma
This study is a prospective clinical study. The purpose is to explore the efficacy and safety of Envafolimab combined with chemotherapy for neoadjuvant treatment or conversion treatment of locally advanced head and neck squamous…
- Trial name
- NCT06218004
- Testing
- Envafolimab combined with chemotherapy
- Volunteers
- 40 people
- Sponsor
- Hairong Liu
Hepatocellular Carcinoma
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
This is a multi-center, single arm study to evaluate the efficacy and safety of donafenib in combination with envafolimab treatment in patients with high risk of recurrent hepatocellular carcinoma after radical surgery.
- Trial name
- NCT06498622
- Testing
- Donafenib + Envafolimab
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Anhui Provincial Hospital
Solid Tumors, Non-small Cell Lung Cancer
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
This is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced solid tumors.
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05024214
- Testing
- Lenvatinib + Envafolimab, Sunitinib
- Where
- 23 sites in China
- Volunteers
- 170 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Squamous Non-small Cell Lung Cancer
Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC
This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Envafolimab combined with standard platinum containing dual drug chemotherapy and Recombinant Human Endostatin in…
- Trial name
- NCT05243355
- Testing
- "Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin"
- Where
- 2 sites in China
- Volunteers
- 46 people
- Sponsor
- Qilu Hospital of Shandong University
Advanced Endometrial Cancer
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab…
- Trial name
- NCT05112991
- Testing
- Envafolimab+Lenvatinib, Envafolimab
- Where
- 19 sites in China
- Volunteers
- 108 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Gallbladder Cancer
Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC
The TOPAZ-1 study compared the advantages and disadvantages of immune checkpoint inhibitor anti-PD-L1 antibody combined with Gem/Cis chemotherapy (Gemcitabine and Cisplatin) and Gem/Cis chemotherapy alone in first-line treatment…
- Trial name
- NCT06013943
- Testing
- Envafolimab+Gemox
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Gastric Cancer
Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
To observe and evaluate the neoadjuvant treatment of Envafolimab combined with Fruquintinib and chemotherapy for locally advanced gastric/gastroesophageal junction carcinoma
- Trial name
- NCT06791083
- Testing
- Envafolimab, Fruquintinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Advanced Pancreatic Cancer
Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer
This is a single-arm, open-label, exploratory study to evaluate efficacy and safety of envafolimab combined with endostar and nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer.
- Trial name
- NCT05298020
- Testing
- Envafolimab, Endostar, Nab paclitaxel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Non-small Cell Lung Cancer
Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC
This is a prospective, single-arm, open-label, interventional clinical study, aimed at exploring the efficacy and safety of sequential Envafolimab immunotherapy after patients with ctDNA EGFR mutation clearance and achieved…
- Trial name
- NCT05534113
- Testing
- Almonertinib Envafolimab
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pancreatic Cancer, Radiotherapy
Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC
This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of concurrent radiotherapy with envafolimab and capecitabine in locally advanced pancreatic cancer.Eligibility patients will receive…
- Conditions
- Pancreatic Cancer, Radiotherapy, Envafolimab, Capecitabine
- Trial name
- NCT06202014
- Testing
- concurrent radiotherapy with envafolimab and capecitabine
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Cervical Cancer
Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer
This is a single-arm, single-center, exploratory study, the purpose of this study is to evaluate the efficacy and safety of envafolimab combined with Chemoradiotherapy in participants with locally advanced cervical cancer.
- Trial name
- NCT05799469
- Testing
- Envafolimab, Cisplatin, External Beam Radiotherapy (EBRT)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing University Cancer Hospital
Immunotherapy;Envafolimab; Esophageal Cancer
Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer
Big breakthroughs have been made in the combination therapy of immune checkpoint inhibitors when it comes to the neoadjuvant therapy of esophageal cancer.
- Trial name
- NCT05828381
- Testing
- Envafolimab, Abraxane, Cisplatin
- Volunteers
- 33 people
- Sponsor
- Fujian Medical University Union Hospital
Solid Tumor
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
An open, single-arm, multi-center Phase II clinical study of ENVAFOLIMAB single-agent treatment in patients with advanced solid tumors,to compare the overall response rate of TMB-high and TMB-Low,to determine the cut off value…
- Trial name
- NCT04891198
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 126 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Non Small Cell Lung Cancer, Lung Neoplasms
SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC
This is a prospective, single-arm phase II clinical study. It intends to evaluate the efficacy and safety of stereotactic radiation therapy (SRT) combined with envafolimab and endostar as first-line treatment in stage IV…
- Trial name
- Endouble 2 (NCT07818304)
- Testing
- Stereotactic Radiation Therapy, Envafolimab, Endostar
- Where
- China
- Volunteers
- 61 people
- Sponsor
- The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer Stage III
A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
This is a prospective, single arm, phase II study to evaluate the efficacy and safety of Envafolimab in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not progressed after prior…
- Trial name
- NCT05414630
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Cancer Hospital
Epithelial Ovarian Cancer
A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
The primary objective of this study is to evaluate the efficacy and safety of cyclophosphamide and bevacizumab in combination with Envafolimab in the treatment of recurrent epithelial ovarian cancer (EOC), fallopian tube cancer…
- Trial name
- NCT06010667
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hebei Medical University Fourth Hospital
Locally Advanced Nasopharyngeal Carcinoma, Envafolimab
Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy.
- Conditions
- Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemotherapy, PD-L1
- Trial name
- NCT05397769
- Testing
- Envafolimab Plus Chemoradiotherapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Colon Cancer, Neoadjuvant Therapy
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
There exists substantial evidence suggesting that patients diagnosed with MSI-H/dMMR colorectal cancer can derive benefits from immunotherapy in the management of advanced colorectal cancer.
- Conditions
- Colon Cancer, Neoadjuvant Therapy, Immunotherapy
- Trial name
- NCT06014372
- Testing
- Envafolimab, CAPEOX
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Biliary Tract Neoplasms
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
This is a Randomized, Open-Label, Multicenter Phase 2 Study to access the efficacy and safety of Envafolimab in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients…
- Trial name
- NCT04910386
- Testing
- Envafolimab plus Gemcitabine&Cisplatin, Gemcitabine&Cisplatin
- Volunteers
- 126 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Advanced or Metastatic Solid Tumors
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.
This is an open label, two-part, multicenter, multi-regional phase I trial to investigate the safety, tolerability, and PK of KGX101 monotherapy and combination therapy with Envafolimab in patients with advanced or metastatic…
- Trial name
- NCT06074497
- Testing
- KGX101- Cohort -1, KGX101- Cohort 1, KGX101- Cohort 2
- Where
- 3 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Kangabio AUSTRALIA LTD PTY